Clinical trials: Breath Holding
- Condition Breath Holding
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
This study is a 2 treatment period, single dose crossover, gamma scintigraphy study investigating the deposition in the lungs of a Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler.
- Trial name
- NCT03740373
- Testing
- BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold, BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca